124 STAT. 502 PUBLIC LAW 111–148—MAR. 23, 2010 ‘‘(F) MAJORITY REQUIRED FOR ADOPTION.—A joint reso- lution considered under this subsection shall require an affirmative vote of three-fifths of the Members, duly chosen and sworn, for adoption. ‘‘(3) TERMINATION.—If a joint resolution described in para- graph (1) is enacted not later than August 15, 2017— ‘‘(A) the Chief Actuary of the Medicare & Medicaid Services shall not— ‘‘(i) make any determinations under subsection (c)(6) after May 1, 2017; or ‘‘(ii) provide any opinion pursuant to subsection (c)(3)(B)(iii) after January 16, 2018; ‘‘(B) the Board shall not submit any proposals or advisory reports to Congress under this section after January 16, 2018; and ‘‘(C) the Board and the consumer advisory council under subsection (k) shall terminate on August 16, 2018. ‘‘(g) BOARD MEMBERSHIP; TERMS OF OFFICE; CHAIRPERSON; REMOVAL.— ‘‘(1) MEMBERSHIP.— ‘‘(A) IN GENERAL.—The Board shall be composed of— ‘‘(i) 15 members appointed by the President, by and with the advice and consent of the Senate; and ‘‘(ii) the Secretary, the Administrator of the Center for Medicare & Medicaid Services, and the Adminis- trator of the Health Resources and Services Adminis- tration, all of whom shall serve ex officio as nonvoting members of the Board. ‘‘(B) QUALIFICATIONS.— ‘‘(i) IN GENERAL.—The appointed membership of the Board shall include individuals with national rec- ognition for their expertise in health finance and economics, actuarial science, health facility manage- ment, health plans and integrated delivery systems, reimbursement of health facilities, allopathic and osteo- pathic physicians, and other providers of health serv- ices, and other related fields, who provide a mix of different professionals, broad geographic representa- tion, and a balance between urban and rural represent- atives. ‘‘(ii) INCLUSION.—The appointed membership of the Board shall include (but not be limited to) physicians and other health professionals, experts in the area of pharmaco-economics or prescription drug benefit pro- grams, employers, third-party payers, individuals skilled in the conduct and interpretation of biomedical, health services, and health economics research and expertise in outcomes and effectiveness research and technology assessment. Such membership shall also include representatives of consumers and the elderly. ‘‘(iii) MAJORITY NONPROVIDERS.—Individuals who are directly involved in the provision or management of the delivery of items and services covered under this title shall not constitute a majority of the appointed membership of the Board. ‘‘(C) ETHICAL DISCLOSURE.—The President shall estab- lish a system for public disclosure by appointed members President. Public information. President. Appointments. Deadlines.
